Pseudocholinesterase deficiency is a rare enzymatic alteration that leads to an increased risk of adverse effects from certain muscle relaxants, such as mivacurium and succinylcholine, used during general anesthesia in certain countries.
Mivacurium and succinylcholine (Adverse Reactions)
Mivacurium is a short-acting, non-depolarizing neuromuscular blocking agent used as an adjunct in general anesthesia to relax skeletal muscles. This medication works by competitively binding to cholinergic receptors at the motor endplate, blocking the action of acetylcholine, and consequently inhibiting neuromuscular transmission.
Meanwhile, succinylcholine (or suxamethonium) is an ultra-short-acting muscle relaxant belonging to the class of depolarizing neuromuscular blocking agents, mainly used to facilitate tracheal intubation and muscle relaxation in surgical procedures.
Both mivacurium and succinylcholine are rapidly metabolized by enzymatic hydrolysis catalyzed by the enzyme pseudocholinesterase or butyrylcholinesterase (BChE) in plasma. However, a rare but potentially serious adverse effect is prolonged apnea after administration of these agents under general anesthesia. This risk is associated with defects in the BChE enzyme, which may be caused by mutations in the BCHE gene that encodes this enzyme. Generally, people with BChE deficiency do not show symptoms until they receive drugs such as mivacurium or succinylcholine.
If you have a family history of BChE deficiency or a family member who has experienced problems related to anesthesia, it is essential to inform your doctor before undergoing any procedure that requires anesthesia.
TRADE NAMES
- Mivacron® (mivacurium)
- Anectine® (succinylcholine)
- Quelicin® (succinylcholine)
Genes analyzed
Bibliography
Alvarellos ML, McDonagh EM, Patel S, et al. PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2015 Dec;25(12):622-30.
Trujillo R, West WP. Pseudocholinesterase Deficiency. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Wichmann S, Færk G, Bundgaard JR, Gätke MR. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene. Pharmacogenet Genomics. 2016 Jul;26(7):351-6.
Zhu GD, Dawson E, Huskey A, et al. Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine. Pharmgenomics Pers Med. 2020 Sep 30;13:405-414.
